Gregory L. Beatty, MD, PhD
Perelman Center for Advanced Medicine
South Pavilion, Rm 8-107
3400 Civic Center Blvd
Philadelphia, PA 19104-5156
Bucknell University, 1995.
University of Pennsylvania, 2000.
University of Pennsylvania, 2004.
Description of Clinical ExpertiseDr. Beatty's clinical expertise is in the area of early clinical trials for the treatment of gastrointestinal malignancies including pancreas, esophageal and colon carcinomas. He has led the first clinical study of CD40 immunotherapy for pancreas cancer, the first in-human study of a novel inhibitor of indoleamine 2,3 deoxygenase, and is currently working to translate novel T cell adoptive therapies for pancreas cancer.
In addition to the translation of immunotherapeutic strategies for the treatment of gastrointestinal malignancies, Dr. Beatty's clinical research is focused on translating novel imaging strategies to the clinic to understand therapeutic responses to immunotherapy. His research also collaborates with radiation oncology to understand the role of radiation for activating immune responses against pancreatic carcinoma.
Based on early clinical findings supporting a role for immunotherapy in pancreatic carcinoma, Dr. Beatty's laboratory is using preclinical models of cancer to advance our understanding of the role of the immune system in regulating tumor biology with the primary goal to inform the development of novel immunotherapeutics for translation to the clinical setting.
Description of Other ExpertiseCurrent members of my laboratory include:
1. Meredith Stone, post-doctoral researcher
2. Jason Liu, combined degree student
3. Jae Lee, combined degree student
4. Renecca Kim, medical student
5. Yan Li, research specialist
6. Xiaoqing Pan, research specialist
7. Kathleen Graham, research specialist, animal studies manager
8, Devora Delman, research specialist, lab manager
9. Anni Liu, undergraduate student
10. Thomas Buckingham, undergraduate student
Past members of my laboratory include:
1. Santiago Lombo Luque, research specialist
2. Amy Shyu, masters student
3. Kristen Schwab, medical student
4. Michael Chuang, undergraduate student
5. Patrick Guirnalda, post-doctoral researcher
6. Whitney Gladney, Ph.D., post-doctoral researcher
7. Graham Tooker, post-baccalaureate student
8. Kevin Alicea Torres, post-baccalaureate student
9. Dawson Knoblock, Ph.D., post-doctoral researcher
10. Irene Park, undergraduate student
11. Kristen Long, Ph.D., post-doctoral researcher
12. Anusha Kalbasi, M.D., radiation oncology resident
13. Fee Bengsch, post-doctoral researcher
14. Evan Tooker, masters student
15. Chad Komar, undergraduate/masters student
16. Shabnam Eghbali, undergraduate student
17. Robert Hu, undergraduate student
Description of Research ExpertiseMy laboratory incorporates both basic science research and clinical investigation to examine the role of innate immunity, in particular monocytes/macrophages, in regulating tumor biology in pancreas cancer as well as other upper gastrointestinal malignancies. Our central hypothesis is that macrophages are key regulators of tumor biology.
Clinical research in the laboratory uses patient-derived samples to understand the role of macrophage biology in metastatic disease and therapeutic efficacy.
Preclinical research in the laboratory uses a genetically engineered mouse model of pancreas cancer in combination with advanced imaging strategies to study macrophage biology within the tumor microenvironment. This preclinical research platform allows for the study of basic immune biology within the tumor microenvironment as well as the rapid screening of novel immunotherapeutic strategies, including cell and gene therapies, for the treatment of cancer.
Studies in the laboratory focus on understanding 1) the signaling pathways that regulate cross-talk between macrophages and tumor cells in vivo, 2) the role of hematopoietic and non-hematopoietic cells in regulating macrophage biology within tumors, 3) the cellular trafficking of macrophages to primary and metastatic lesions, 4) strategies to harness macrophages for anti-tumor therapy, and 5) the impact of chemotherapy/radiation therapy on macrophage biology within tumors.
Selected PublicationsVonderheide RH, Bajor DL, Winograd R, Evans RA, Bayne LJ, Beatty GL.: CD40 immunotherapy for pancreatic cancer. Cancer Immunol Immunother 62(5): 949-54, May 2013.
Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, Zhao Y, Kalos M, June CH.: T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res 1(1): 26-31, Jul 2013
Bayne, L.J., Beatty, G.L., Jhala, N., Clark, C.E., Rhim, A.D., Stanger, B.Z., and R.H. Vonderheide : Tumor-derived granulocyte-macrophage colony stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 21: 822-35. Jun 12 2012
Rhim AD, Mirek ET, Aiello, NM, Maitra A, Bailey J.M, McCallister F, Reichert M, Beatty GL, Rustgi AK, Vonderheide RH, Leach SD, BZ Stanger: EMT and dissemination precede pancreatic tumor formation. Cell 148: 349-61, Jan 20 2012.
Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun WJ, Huhn RD, Song WR, Li DG, Sharp LL, Torigian DA, O'Dwyer PJ, Vonderheide RH: CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans. Science 331(6024): 1612-1616, Mar 25 2011.
Beatty GL, Smith JS, Reshef R, Patel KP, Colligon TA, Vance BA, Frey NV, Johnson FB, Porter DL, Vonderheide RH: Functional Unresponsiveness and Replicative Senescence of Myeloid Leukemia Antigen-specific CD8(+) T Cells After Allogeneic Stem Cell Transplantation. Clin Cancer Res 15(15): 4944-4953, Aug 1 2009.
Clark CE, Beatty GL, Vonderheide RH: Immunosurveillance of pancreatic adenocarcinoma: Insights from genetically engineered mouse models of cancer. Cancer Lett 279(1): 1-7, Jun 28 2009.
Dominiecki ME, Beatty GL, Pan ZK, Neeson P, Paterson Y: Tumor sensitivity to IFN-gamma is required for successful antigen-specific immunotherapy of a transplantable mouse tumor model for HPV-transformed tumors. Cancer Immunol Immunother 54(5): 477-488, May 2005.
Beatty GL, Paterson Y: IFN-gamma-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4(+) T cells requires tumor responsiveness to IFN-gamma. J Immunol 166(4): 2276-2282, Feb 15 2001.
Beatty GL, Paterson Y: IFN-gamma can promote tumor evasion of the immune system in vivo by down-regulating cellular levels of an endogenous tumor antigen. J Immunol 165(10): 5502-5508, Nov 15 2000.
Beatty GL, Paterson Y: IFN-gamma signaling in antigen loss tumor variants plays a role in the bystander killing effect induced by recombinant Listeria. Federation of American Societies for Experimental Biology Journal 13(4): A297-A297, MAR 12 1999.